Strongbridge Biopharma's basic earnings per share (Basic EPS) for the
three
months ended in Jun. 2021 was $-0.20.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.50.
Strongbridge Biopharma's EPS without NRI for the
three
months ended in Jun. 2021 was $-0.21.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2021 was -0.75.
During the past 3 years, the average EPS without NRIGrowth Rate was 36.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 8 years, Strongbridge Biopharma's highest 3-Year average EPS without NRI Growth Rate was 36.90% per year. The lowest was -37.40% per year. And the median was -7.80% per year.
Strongbridge Biopharma EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Strongbridge Biopharma's Basic EPS for the fiscal year that ended in Dec. 2020 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Strongbridge Biopharma EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Strongbridge Biopharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Strongbridge Biopharma (Strongbridge Biopharma) Business Description
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBBP has been successfully added to your 